Suppr超能文献

感染多重耐药菌的囊性纤维化患者肺部加重的预测因素。

Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.

作者信息

Block J K, Vandemheen K L, Tullis E, Fergusson D, Doucette S, Haase D, Berthiaume Y, Brown N, Wilcox P, Bye P, Bell S, Noseworthy M, Pedder L, Freitag A, Paterson N, Aaron S D

机构信息

Ottawa Hospital, General Campus, 501 Smyth Road, Mailbox 211, Ottawa, Ontario, Canada K1H 8L6.

出版信息

Thorax. 2006 Nov;61(11):969-74. doi: 10.1136/thx.2006.061366. Epub 2006 Jul 14.

Abstract

BACKGROUND

This study examined characteristics of adult and adolescent patients with cystic fibrosis (CF) to determine factors associated with an increased risk of pulmonary exacerbations.

METHODS

249 patients with CF infected with multidrug resistant bacteria were recruited and prospectively followed for up to 4.5 years until they experienced a pulmonary exacerbation severe enough to require intravenous antibiotics. Multivariable regression analyses were used to compare the characteristics of patients who experienced an exacerbation with those who did not.

RESULTS

124 of the 249 patients (50%) developed a pulmonary exacerbation during the first year and 154 (62%) experienced an exacerbation during the 4.5 year study period. Factors predictive of exacerbations in a multivariable survival model were younger age (OR 0.98, 95% CI 0.96 to 0.99), female sex (OR 1.45, 95% CI 1.07 to 1.95), lower forced expiratory volume in 1 second (FEV(1)) (OR 0.98, 95% CI 0.97 to 0.99), and a previous history of multiple pulmonary exacerbations (OR 3.16, 95% CI 1.93 to 5.17). Chronic use of inhaled corticosteroids was associated with an increased risk of exacerbation (OR 1.92, 95% CI 1.00 to 3.71) during the first study year.

CONCLUSIONS

Patients who experience pulmonary exacerbations are more likely to be younger, female, using inhaled steroids, have a lower FEV(1), and a history of multiple previous exacerbations. It is hoped that knowledge of these risk factors will allow better identification and closer monitoring of patients who are at high risk of exacerbations.

摘要

背景

本研究调查了成年和青少年囊性纤维化(CF)患者的特征,以确定与肺部加重风险增加相关的因素。

方法

招募了249例感染多重耐药菌的CF患者,并对其进行了长达4.5年的前瞻性随访,直至他们经历了严重到需要静脉使用抗生素的肺部加重。采用多变量回归分析比较发生加重的患者与未发生加重的患者的特征。

结果

249例患者中有124例(50%)在第一年出现肺部加重,154例(62%)在4.5年的研究期间出现加重。多变量生存模型中预测加重的因素包括年龄较小(比值比[OR]0.98,95%置信区间[CI]0.96至0.99)、女性(OR 1.45,95%CI 1.07至1.95)、第一秒用力呼气量(FEV₁)较低(OR 0.98,95%CI 0.97至0.99)以及既往有多次肺部加重史(OR 3.16,95%CI 1.93至5.17)。在研究的第一年,长期使用吸入性糖皮质激素与加重风险增加相关(OR 1.92,95%CI 1.00至3.71)。

结论

经历肺部加重的患者更可能年龄较小、为女性、使用吸入性类固醇、FEV₁较低且既往有多次加重史。希望了解这些危险因素将有助于更好地识别和密切监测有加重高风险的患者。

相似文献

1
Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria.
Thorax. 2006 Nov;61(11):969-74. doi: 10.1136/thx.2006.061366. Epub 2006 Jul 14.
2
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.
Thorax. 2011 Aug;66(8):680-5. doi: 10.1136/thx.2011.161117. Epub 2011 Jun 15.
3
Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations.
J Cyst Fibros. 2015 Nov;14(6):770-6. doi: 10.1016/j.jcf.2015.07.010. Epub 2015 Aug 9.
4
Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Respir Med. 2009 Mar;103(3):407-13. doi: 10.1016/j.rmed.2008.09.024. Epub 2008 Nov 22.
5
Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.
J Cyst Fibros. 2012 Jan;11(1):8-13. doi: 10.1016/j.jcf.2011.07.008. Epub 2011 Aug 16.
7
Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers.
Pediatr Pulmonol. 2011 Sep;46(9):870-81. doi: 10.1002/ppul.21442. Epub 2011 Apr 4.
8
Pulmonary exacerbations in cystic fibrosis.
Pediatr Pulmonol. 2004 May;37(5):400-6. doi: 10.1002/ppul.20023.
9
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.
Eur Respir J. 2012 Jul;40(1):61-6. doi: 10.1183/09031936.00159111. Epub 2011 Dec 1.

引用本文的文献

1
Corticosteroids modulate biofilm formation and virulence of .
Biofilm. 2025 May 29;9:100289. doi: 10.1016/j.bioflm.2025.100289. eCollection 2025 Jun.
3
Aiming to Improve Equity in Pulmonary Health: Cystic Fibrosis.
Clin Chest Med. 2023 Sep;44(3):555-573. doi: 10.1016/j.ccm.2023.03.011. Epub 2023 May 8.
4
Large pH oscillations promote host defense against human airways infection.
J Exp Med. 2021 Apr 5;218(4). doi: 10.1084/jem.20201831.
5
Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis.
Front Pharmacol. 2020 Sep 11;11:576293. doi: 10.3389/fphar.2020.576293. eCollection 2020.
6
The demographics of adverse outcomes in cystic fibrosis.
Pediatr Pulmonol. 2019 Nov;54 Suppl 3(Suppl 3):S74-S83. doi: 10.1002/ppul.24434.
7
The Estrogen-Induced miR-19 Downregulates Secretory Leucoprotease Inhibitor Expression in Monocytes.
J Innate Immun. 2020;12(1):90-102. doi: 10.1159/000500419. Epub 2019 Jul 2.
8
Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis.
J Cyst Fibros. 2019 Nov;18(6):808-816. doi: 10.1016/j.jcf.2019.02.012. Epub 2019 Mar 21.

本文引用的文献

1
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis.
Am J Respir Crit Care Med. 2006 Jun 15;173(12):1356-62. doi: 10.1164/rccm.200511-1808OC. Epub 2006 Mar 23.
2
Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.
Respiration. 2006;73(1):27-33. doi: 10.1159/000087686. Epub 2005 Aug 17.
4
The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis.
Am J Respir Crit Care Med. 2005 Jul 1;172(1):99-104. doi: 10.1164/rccm.200409-1244OC. Epub 2005 Apr 14.
5
One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis.
Am J Respir Crit Care Med. 2005 Jan 15;171(2):158-64. doi: 10.1164/rccm.200405-667OC. Epub 2004 Oct 22.
6
Pathophysiology and management of pulmonary infections in cystic fibrosis.
Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51. doi: 10.1164/rccm.200304-505SO.
8
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 1):1550-5. doi: 10.1164/rccm.200202-087OC. Epub 2002 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验